Nodal marginal zone lymphoma: Difference between revisions
No edit summary |
|||
| Line 99: | Line 99: | ||
=== Other Diagnostic Studies === | === Other Diagnostic Studies === | ||
== Treatment == | ==Treatment== | ||
=== | ===Medical Therapy=== | ||
==== | {| style="border: 0px; font-size: 90%; margin: 3px;" align=center | ||
|+ '''Treatment of nodal marginal zone lymphoma | |||
! style="background: #4479BA; color:#FFF;" | Therapy | |||
! style="background: #4479BA; color:#FFF;" | Description | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | Watchful waiting | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* May not need treatment right away unless they have symptoms | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | Chemotherapy | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
* Monotherapy: [[Chlorambucil]] {{or}} [[Fludarabine]] | |||
* Combination therapy : | |||
:* CVP – [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Prednisone]] | |||
:* CHOP – [[Cyclophosphamide]] {{and}} [[Doxorubicin]] {{and}} [[Vincristine]] {{and}} [[Prednisone]] | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
|} | |||
==References== | ==References== | ||
Revision as of 16:03, 4 March 2016
For patient information, click Insert page name here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Synonyms and keywords:: NMZL; Nodal marginal zone B cell lymphoma; Monocytoid B-cell lymphoma; Nodal monocytoid B-cell lymphoma
Overview
Pathophysiology
Genetics
Associated Conditions
Gross Pathology
Microscopic Pathology
Causes
There are no established causes for nodal marginal zone lymphoma.
Differentiating type page name here from other Diseases
Epidemiology and Demographics
Age
The incidence of nodal marginal zone lymphoma increases with age; the median age at diagnosis is 60 years.
Gender
Females are more commonly affected with nodal marginal zone lymphoma than males.
Risk Factors
There are no established risk factors for nodal marginal zone lymphoma.
Screening
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for nodal marginal zone lymphoma.
Natural History, Complications and Prognosis
Nodal marginal zone lymphoma is often slow growing (indolent). However, it can change (transform) into a more aggressive large cell lymphoma. Nodal marginal zone lymphomas behave slightly more aggressively than MALT lymphomas.
Diagnosis
Diagnostic Criteria
If available, the diagnostic criteria are provided here.
History
A directed history should be obtained to ascertain
Symptoms
Physical Examination
Appearance of the Patient
Vital Signs
Skin
Head
Eyes
Ear
Nose
Mouth
Throat
Heart
Lungs
Abdomen
Extremities
Neurologic
Genitals
Other
Laboratory Findings
Electrolyte and Biomarker Studies
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
| Therapy | Description |
|---|---|
| Watchful waiting |
|
| Chemotherapy |
|